Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COSTA: Belantamab Mafodotin in Relapsed/Refractory Myeloma
NCT05874193Phase 2Withdrawn
- Start
- Nov 2026
- Primary completion
- Oct 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of belantamab mafodotin in multiple myeloma (MM). Primary endpoint: Feasibility of providing Belantamab mafodotin every 6 weeks. Planned start Nov 2026; status: withdrawn.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05874193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05874193.